Chairman, President & CEO
Ken Song, M.D. is chairman, president and CEO of Candid Therapeutics, a clinical stage biotech company focused on innovative drug therapies. Previously, he served as president, CEO and board director of RayzeBio from the company’s July 2020 launch through its $350 million+ IPO in September 2023 and then $4.1 billion acquisition by BMS in February 2024. He currently serves as the chairman of the boards of directors at Ablaze Pharmaceuticals and Averto Medical. Previously, Ken served as president, CEO and board director of Metacrine, as CEO and board director of Ariosa Diagnostics (acquired by Roche) and as executive chairman of the board at Omniome (acquired by PacBio). Earlier in his career, Ken was a venture capitalist at Venrock and a consultant at McKinsey & Company. Ken holds a B.S. in biology from MIT and an M.D. from UC San Francisco. Ken trained in internal medicine at UCSF and gastroenterology and hepatology at the University of Washington. He was a scientific research fellow at the Fred Hutchinson Cancer Center.